Nektar Therapeutics NKTR
At closeNov 13, 2026, 8:35 AM EST
Pre-market · Nov 13, 8:35 AM ET
- YTD
- -11.90%
- 1 year
- -35.41%
- Market cap
- 1.27B
- Revenue (ttm)
- 54.59M
- Profit margin
- -287.84%
- EPS (ttm)
- -18.96
- Shares out
- 34.14M
- Forward P/E
- -3.62
- YTD return
- -11.90%
- 1-year return
- -35.41%
- Volume
- 769.63K
- Avg volume
- 1.10M
- Open
- 38.32
- Previous close
- 37.25
- Day's range
- 37.01 – 38.32
- 52-week range
- 33.40 – 109.00
- Beta
- 1.42
- Price target
- 133.08 (+257.3%)
- Earnings date
- Mar 11, 2027
5D +1.01 (+2.75%)
Key statistics
- Enterprise value
- 764.05M
- PEG ratio
- 0.31
- Price / sales
- 23.30
- Price / book
- 1.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -9.30%
- Free cash flow
- -134.77M
- Total cash
- 684.34M
- Total debt
- 135.93M
- Return on equity
- -35.76%
- Short % of float
- 21.84%
- 50-day average
- 49.97
- 200-day average
- 65.04
Analyst view
- Target (low)
- 50.00
- Target (mean)
- 133.08
- Target (high)
- 192.00
- Strong buy1
- Buy10
- Hold4
- Sell0
- Strong sell0
Next earnings
Mar 11, 2027
Expected Mar 11, 2027. Consensus EPS estimate -2.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2027 | Dec 30, 2026 | -2.77 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -2.07 | -1.63 | +0.44 | +21.26% |
| Aug 13, 2026 | Jun 30, 2026 | -1.97 | -1.23 | +0.74 | +37.56% |
| May 7, 2026 | Mar 31, 2026 | -1.58 | -1.82 | -0.24 | -15.02% |
| Mar 12, 2026 | Dec 31, 2025 | -2.47 | -1.78 | +0.69 | +28.05% |
| Nov 6, 2025 | Sep 30, 2025 | -2.85 | -1.85 | +1.00 | +35.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Neutral |
| Oct 12, 2026 | Leerink Partners | init | — | Outperform |
| Oct 9, 2026 | BTIG | reit | Buy | Buy |
| Oct 9, 2026 | Raymond James | init | — | Market Perform |
| Oct 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 28, 2026 | BTIG | reit | Buy | Buy |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nektar.com
News
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript 
What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call 
Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates 
Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M 
Nektar Therapeutics Announces Third Quarter 2026 Financial Results 
Nektar Therapeutics to Participate in Two Investor Conferences in November 
CenterBook Partners LP Buys 26,346 Shares of Nektar Therapeutics $NKTR 
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53 
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130 
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
Your note
Sign in to keep a note on NKTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ROBIN HOWARD W | Chief Executive Officer | Sale | Aug 17, 2026 | 54,655 |
| WILSON MARK ANDREW | Officer | Sale | Nov 24, 2025 | 21,585 |
| ZALEVSKY JONATHAN | Officer | Sale | Aug 17, 2026 | 9,570 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.00% | 5,121,441 | 190.77M | Sep 29, 2026 |
| Two Seas Capital Lp | 9.80% | 3,345,978 | 124.64M | Sep 29, 2026 |
| Blackrock Inc. | 8.62% | 2,941,851 | 109.58M | Jun 29, 2026 |
| BVF Inc. | 7.00% | 2,391,075 | 89.07M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.38% | 1,496,849 | 55.76M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.52% | 1,202,004 | 44.77M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.42% | 1,850,478 | 68.93M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 1,075,108 | 40.05M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.86% | 975,224 | 36.33M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.61% | 892,637 | 33.25M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.47% | 500,351 | 18.64M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.24% | 424,554 | 15.81M | Sep 29, 2026 |